Mitochondrial Dynamics Regulators (MFN1, MFN2, OPA1, DRP1) (MFN1/2, OPA1, DRP1)

MFN1, MFN2, OPA1, and DRP1 are major regulators of mitochondrial morphology and function. MFN1 and MFN2 are outer mitochondrial membrane GTPases mediating mitochondrial fusion, while OPA1 is a dynamin-like inner membrane GTPase also involved in cristae organization and fusion of the inner membrane. DRP1 is a dynamin-related GTPase that mediates mitochondrial fission. These proteins are fundamental for maintaining cellular energy homeostasis, regulating apoptosis, neuronal activity, and calcium signaling. Mutations or dysregulation of these targets leads to severe neurodegenerative diseases (e.g., Charcot-Marie-Tooth type 2A for MFN2, autosomal dominant optic atrophy for OPA1), cardiovascular pathology, and metabolic defects. Therapeutic manipulation of fusion/fission balance offers promising avenues for intervention in neurodegeneration, aging, and metabolic syndrome[3][4][5][6].

Other names

Mitofusin-1Mitofusin-2CMT2A protein (Charcot-Marie-Tooth type 2A protein)Optic atrophy protein 1mitochondrial dynamin-like GTPaseDynamin-related protein 1DNM1L

Drugs and compounds aim to enhance mitochondrial fusion (via MFN1/2 or OPA1 activation), inhibit mitochondrial fission (via DRP1 inhibition), modulate post-translational modifications (e.g., ubiquitination by Parkin), or regulate the expression and stability of fusion/fission proteins.